Resident Director: Alice Chen, MD, NIH National Cancer Institute
This is a time-limited federal appointment not-to-exceed three years. Candidates must meet all of the following requirements for an appointment in the program:
- M.D. or an equivalent degree with a license to practice medicine in the United States
- Completion of subspecialty training in Medical Oncology at a US accredited institution
- Board certification or eligibility in Medical Oncology
- United States citizenship or permanent residency status or on an ECFMG sponsored VISA
Expected outcomes of training:
- Develop the skills to evaluate promising novel targeted anticancer drugs and develop options to bring into the clinic
- Develop the skills to design and conduct first-in-man or early phase clinical trials, particularly those that incorporate pharmacodynamic and pharmacokinetic endpoints
- Acquire the knowledge of the proper procedures for biospecimen collection and handling
- Familiarity with the concepts and principles of Phase 0 trials
- Develop the skills to critically analyze and accurately report the results of early phase clinical trials
- Develop the skills to apply the principles of pharmacokinetics and state-of-the-art imaging modalities to early phase clinical trials
- Develop the skills to recognize and appreciate the ethical concerns and institutional and governmental regulations pertaining to early phase clinical trials and genomic testing
- Develop the skills to critically evaluate non-clinical properties of novel compounds and to prioritize them for clinical development
- Develop the skills to critically review protocols and proposals (letters of intent) for clinical trials
- Develop the skills to generate rational and effective drug development plans
- Develop the skills to care for patients on early phase clinical trials and assess toxicity and attribution of toxicity
The major objective of the ADTTP program is to provide board certified or eligible medical oncologists advanced training in developmental therapeutics. Trainees will enhance their ability to develop strategies to design and conduct early phase clinical trials of novel targeted investigational agents by bringing to bear state-of-the-science knowledge and technology of developmental therapeutics. The program will provide an excellent opportunity to refine skills in clinical investigation including trial design and methodology, protocol development, execution, and monitoring, conformity with ethical standards, compliance with regulatory policies, and formulation of attainable and pertinent laboratory correlatives.
The ADTTP also provides opportunities to learn state-of-the-science principles and technologies of targeted therapeutics by leveraging NCI resources, including a newly integrated experimental therapeutics program at the NCI Center for Cancer Research (CCR) which conducts first-in-human oncology clinical trials, as well as the broad pre-clinical, clinical, regulatory, and administrative drug development expertise available within the Division of Cancer Treatment and Diagnosis (DCTD) designed to substantively advance the pace of oncologic therapeutics development.
The successful candidate will participate in clinical research conducted at the NIH Clinical Center in the Developmental Therapeutics Clinic (DTC), DCTD. The trainee is expected to spend 40-60 percent of effort in clinical investigation involving inpatients and outpatients at the NIH, including a minimum of 2 days in DTC clinic activities. Trainees will also spend up to 25% of effort in the DCTD Cancer Therapy Evaluation Program (CTEP), particularly in the program’s Investigational Drug Branch (IDB). Under the mentorship of one or more IDB senior investigators, trainees will broaden their knowledge of new drug development, including aspects such as agent selection and prioritization, preparation of drug development plans, protocol development and review, IND requirements, adverse events assessment, study monitoring, and data analysis and reporting
Applicants can submit applications on line. Application materials will include:
- Curriculum vitae
- Three letters of recommendation, preferably one from the Medical Oncology training program director or supervisor of last professional position.
- Permanent Residency documentation
- Personal statement of research goals (concise one-page description of research interests and goals and how these relate to the DCTD Clinical Oncology Advanced Developmental Therapeutics Training Program
Submit applications to: Applications should be submitted through the Electronic Residency Application Service (ERAS) System. After review of completed applications, qualified candidates may be invited for interviews and to meet staff and residents.
More detailed information about the program is available at: https://dtc.cancer.gov/fellowship_opportunities/default.htm